ADARx Pharmaceuticals, Inc. (ADRX)
ADARx Pharmaceuticals Market Cap : 1.359B for Nov. 20, 2026
Market Cap Chart
Historical Market Cap Data
| Date | Value |
|---|---|
| November 19, 2026 | 1.519B |
| November 18, 2026 | 1.375B |
| November 17, 2026 | 1.482B |
| November 16, 2026 | 1.502B |
| November 13, 2026 | 1.523B |
| November 12, 2026 | 1.599B |
| November 11, 2026 | 1.427B |
| November 10, 2026 | 1.455B |
| November 09, 2026 | 1.474B |
| November 06, 2026 | 1.413B |
| November 05, 2026 | 1.419B |
| November 04, 2026 | 1.598B |
| November 03, 2026 | 1.718B |
| November 02, 2026 | 1.683B |
| October 30, 2026 | 1.816B |
| October 29, 2026 | 1.906B |
| October 28, 2026 | 1.917B |
| October 27, 2026 | 1.936B |
| October 26, 2026 | 1.902B |
| October 23, 2026 | 1.883B |
| October 22, 2026 | 1.888B |
| Date | Value |
|---|---|
| October 21, 2026 | 1.830B |
| October 20, 2026 | 1.888B |
| October 19, 2026 | 1.883B |
| October 16, 2026 | 1.885B |
| October 15, 2026 | 1.890B |
| October 14, 2026 | 1.904B |
| October 13, 2026 | 1.890B |
| October 12, 2026 | 1.919B |
| October 09, 2026 | 1.899B |
| October 08, 2026 | 1.888B |
| October 07, 2026 | 1.851B |
| October 06, 2026 | 1.984B |
| October 05, 2026 | 2.035B |
| October 02, 2026 | 1.949B |
| October 01, 2026 | 2.087B |
| September 30, 2026 | 2.130B |
| September 29, 2026 | 2.204B |
| September 28, 2026 | 2.146B |
| September 25, 2026 | 2.067B |
| September 24, 2026 | 1.816B |
Market Capitalization Definition
Market Capitalization measures the total value of a company based on their stock price multiplied by the shares outstanding. This metric is important because it gives you an idea of the size of a company, and how the size has changed over time. When studying companies from a relative basis, it would make sense to compare companies that have a similar market capitalization because factors like market share, economies of scale, and business models would also be similar.
Market Cap Range, Past 5 Years
Market Cap Benchmarks
| Korsana Biosciences, Inc. | 1.700B |
| IRulya Therapeutics, Inc. | 40.61M |
| PepGen Inc. | 259.04M |
| Q32 Bio, Inc. | 249.60M |
| Bridgebio Oncology Therapeutics, Inc. | 145.63M |
Market Cap Related Metrics
| PS Ratio | 255.06 |
| PEG Ratio | -0.0273 |
| Price to Book Value | 2.366 |
| Price to Free Cash Flow | 5.763 |
| Price | 12.67 |
| Earnings Yield | -7.09% |
| PEGY Ratio | -0.0273 |